While semaglutide itself does not directly cause photosensitivity, the profound physiological changes brought about by rapid weight loss, the challenges of maintaining hydration amidst GI side effects, and the potential for photosensitizing co-medications can significantly increase an individual's vulnerability to UV damage
isolated nutrients may lack that synergy
Many people experience this pattern at 0.25 mg or 0.5 mg of semaglutide
Roughly 40-60% of patients who start weekly injectable semaglutide or tirzepatide stop within a year, with injection burden cited as a contributing factor in self-reported survey data
"The message would still need to be for pregnant women and those planning pregnancy to follow the label and their clinicians' advice regarding GLP-1 when pregnant or planning pregnancy," she said
[28] A 2014 meta-analysis found no evidence for increased pancreatic cancer risk in people treated with DPP-4 inhibitors, but owing to the modest amount of data available, the authors were unable to completely exclude possibly increased risk